Number of patients (n (%)) with SSc-ILD in the EUSTAR database with 12-month periods of FVC decline, stratified by overall FVC decline from first to last available FVC measurement
| Overall FVC change from baseline to last FVC | One 12-month period with FVC decline | Two or more 12-month periods with FVC decline | ||||
| No decline (n=178) | Moderate decline (n=113) | Significant decline (n=107) | Only moderate declines (n=65) | One significant and ≥1 moderate decline (n=25) | Only significant declines (n=47) | |
| Improved (n=129) | 79 (44) | 22 (20) | 21 (20) | 1 (2) | 3 (12) | 3 (6) |
| Stable (n=206) | 99 (56) | 59 (53) | 29 (27) | 13 (20) | 1 (4) | 5 (11) |
| Moderate decline (n=76) | 28 (25) | 17 (16) | 25 (39) | 1 (4) | 5 (11) | |
| Significant decline (n=75) | 2 (2) | 29 (27) | 23 (35) | 10 (40) | 11 (23) | |
| Major decline (n=49) | 2 (2) | 11 (10) | 3 (5) | 10 (40) | 23 (49) | |
Overall FVC change from baseline to last FVC: major decline (FVC decline of >20%); significant decline (FVC decline of >10 and ≤20%); moderate decline (FVC decline of 5% to 10%); stable (FVC decline or improvement of <5%); and improvement (FVC improvement of ≥5%).
EUSTAR, European Scleroderma Trials And Research; FVC, forced vital capacity; SSc-ILD, systemic sclerosis-associated interstitial lung disease.